
Volitionrx Limited (VNRX) Stock Forecast & Price Target
Volitionrx Limited (VNRX) Analyst Ratings
Bulls say
VolitionRX Ltd is poised for significant growth driven by its strategic expansion into the companion animal diagnostic market, particularly with the anticipated introduction of a feline assay that could potentially double its addressable market. The company has successfully initiated revenue generation from its CE-Marked Nu.Q NETs automated assay and has expanded its evaluations to numerous hospitals globally, enhancing its visibility and clinical effectiveness in the human diagnostics space. Furthermore, strategic partnerships with established players like Werfen and Hologic illustrate the company's efforts to scale its human diagnostics licensing strategy, while advancements in its scientific platform bolster both its appeal and operational reach across targeted sectors.
Bears say
VolitionRX Ltd is facing heightened dilution risk, which has prompted a reduction in future price projections from $5.00 to $3.00. The company’s reliance on its Nucleosomics platform for developing blood tests poses financial challenges, particularly as it navigates the costs associated with research and development in an environment where funding may be uncertain. This increased risk and reduced valuation reflect broader concerns about the company's financial health and its ability to achieve sustainable growth within a competitive diagnostics market.
This aggregate rating is based on analysts' research of Volitionrx Limited and is not a guaranteed prediction by Public.com or investment advice.
Volitionrx Limited (VNRX) Analyst Forecast & Price Prediction
Start investing in Volitionrx Limited (VNRX)
Order type
Buy in
Order amount
Est. shares
0 shares